Saniona AB (SANION) - Total Liabilities

Latest as of December 2025: Skr44.58 Million SEK ≈ $4.80 Million USD

Based on the latest financial reports, Saniona AB (SANION) has total liabilities worth Skr44.58 Million SEK (≈ $4.80 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Saniona AB (SANION) cash conversion ratio to assess how effectively this company generates cash.

Saniona AB - Total Liabilities Trend (2012–2025)

This chart illustrates how Saniona AB's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Saniona AB to evaluate the company's liquid asset resilience ratio.

Saniona AB Competitors by Total Liabilities

The table below lists competitors of Saniona AB ranked by their total liabilities.

Company Country Total Liabilities
Halma PLC
LSE:HLMA
UK GBX1.35 Billion
Pitanium Ltd
NASDAQ:PTNM
USA $19.87 Million
Brogent Technologies
TWO:5263
Taiwan NT$2.26 Billion
TYM Corporation
KO:002900
Korea ₩426.47 Billion
Mayfield Group Holdings Ltd
AU:MYG
Australia AU$31.26 Million
Avalue Technology
TWO:3479
Taiwan NT$3.88 Billion
Triplepoint Venture Growth BDC Corp
NYSE:TPVG
USA $486.03 Million
Kaltura Inc
NASDAQ:KLTR
USA $154.89 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Saniona AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SANION company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 13.48 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.07 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Saniona AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Saniona AB (2012–2025)

The table below shows the annual total liabilities of Saniona AB from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr44.58 Million
≈ $4.80 Million
-58.69%
2024-12-31 Skr107.92 Million
≈ $11.61 Million
+25.36%
2023-12-31 Skr86.08 Million
≈ $9.26 Million
-14.76%
2022-12-31 Skr100.99 Million
≈ $10.87 Million
-36.18%
2021-12-31 Skr158.25 Million
≈ $17.03 Million
+78.36%
2020-12-31 Skr88.72 Million
≈ $9.55 Million
+136.20%
2019-12-31 Skr37.56 Million
≈ $4.04 Million
-13.88%
2018-12-31 Skr43.62 Million
≈ $4.69 Million
+305.86%
2017-12-31 Skr10.75 Million
≈ $1.16 Million
-34.93%
2016-12-31 Skr16.52 Million
≈ $1.78 Million
+249.20%
2015-12-31 Skr4.73 Million
≈ $509.02K
-29.19%
2014-12-31 Skr6.68 Million
≈ $718.87K
-53.92%
2013-12-31 Skr14.50 Million
≈ $1.56 Million
+51.63%
2012-12-31 Skr9.56 Million
≈ $1.03 Million
--

About Saniona AB

ST:SANION Sweden Biotechnology
Market Cap
$207.66 Million
Skr1.93 Billion SEK
Market Cap Rank
#16398 Global
#266 in Sweden
Share Price
Skr13.98
Change (1 day)
-0.57%
52-Week Range
Skr7.92 - Skr27.50
All Time High
Skr52.03
About

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more